Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Munish Mehra

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Journal of Huntington'S Disease|June 9, 2020
Additional Safety and Exploratory Efficacy Data at 48 and 60 Months from Open-HART, an Open-Label Extension Study of Pridopidine in Huntington DiseaseAndrew McGarry, Peggy Auinger, Karl Kieburtz, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 16, 2022
Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosisJeffrey A Cohen, Fred D Lublin, Christoper Lock, et al.
Neurology|November 20, 2019
NurOwn, phase 2, randomized, clinical trial in patients with ALS: Safety, clinical, and biomarker resultsJames D Berry, Merit E Cudkowicz, Anthony J Windebank, et al.
Nature Medicine|September 5, 2025
Pridopidine in early-stage manifest Huntington's disease: a phase 3 trialRalf Reilmann, Andrew Feigin, Anne E Rosser, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Journal of Huntington'S Disease|June 9, 2020
Additional Safety and Exploratory Efficacy Data at 48 and 60 Months from Open-HART, an Open-Label Extension Study of Pridopidine in Huntington DiseaseAndrew McGarry, Peggy Auinger, Karl Kieburtz, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 16, 2022
Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosisJeffrey A Cohen, Fred D Lublin, Christoper Lock, et al.
Neurology|November 20, 2019
NurOwn, phase 2, randomized, clinical trial in patients with ALS: Safety, clinical, and biomarker resultsJames D Berry, Merit E Cudkowicz, Anthony J Windebank, et al.
Nature Medicine|September 5, 2025
Pridopidine in early-stage manifest Huntington's disease: a phase 3 trialRalf Reilmann, Andrew Feigin, Anne E Rosser, et al.
Pageof 2